---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-040546"
form_type: "8-K"
ticker: "ABSI"
cik: "0001672688"
company_name: "Absci Corp"
filed_at: "2023-12-04T23:59:59+00:00"
generated_at: "2026-06-07T18:46:52.166007+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Absci announces up to $247M AI antibody collaboration with AstraZeneca for oncology target

## Summary
- Absci to apply its generative AI antibody platform to design an oncology candidate for AstraZeneca.
- Total deal consideration up to $247M, including upfront, R&D funding, milestones, plus royalties on sales.
- Agreement combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.
- Platform aims to reduce drug design-validation cycle to ~6 weeks and expand target universe to GPCRs, ion channels.
- Collaboration follows Absci's recent publication on 'zero-shot' generative AI model for de novo antibody design.

## SEC filing metadata
- accession: 0001628280-23-040546
- form_type: 8-K
- ticker: ABSI
- cik: 0001672688
- company_name: Absci Corp
- filed_at: 2023-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672688/000162828023040546/0001628280-23-040546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672688/000162828023040546/absc-20231204.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-040546
- JSON: https://secwatch.observer/filing/0001628280-23-040546.json
- Plain text: https://secwatch.observer/filing/0001628280-23-040546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.